A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Patients eligible for inclusion in this study have to meet all of the following criteria:
Patients, 18 years of age or older
Competent and able to comprehend, sign and date an Ethics Committee (EC) approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests
Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Histologically proven diagnosis solid tumor
Diagnosis of advanced or locally advanced disease
Patients candidated to receive standard therapy in the following line:
first, second or third-line therapy for colon-rectal cancer in IV stage
first or second-line therapy for gastric cancer in IV stage
primary intent or first-line therapy for pancreatic cancer
first-line therapy for bile duct cancer
first or second-line therapy for hepatocarcinoma
first, second, third, fourth or fifth-line therapy for breast cancer in IV stage
chemotherapy for ovarian cancer in advanced stage (FIGO III-IV) and at the time of first relapse
first or second-line therapy for endometrial cancer in advanced stage (FIGO III-IV)
first or second-line therapy for advanced or locally advanced cervical cancer
therapy for locally advanced or first line therapy for metastatic vulva cancer
first, second or third-line therapy for melanoma (third-line therapy only in BRAF-mutated melanoma)
You may not be if
Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
Patients unable or unwilling to undergo as per protocol assessments at the four planned timepoints
Clareo Health | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
